Related Digital Materials | AME

All filters

Slidesets

RNA Interference Screen Identified Farnesoid X Receptor (FXR) as a Host Dependency Factor for HBV Establishment in Primary Human Hepatocytes- Dr. S. Ghosh

Presented at:

HEP DART 2017

Slidesets

Evidence Supporting Liver Targeting of Tenofovir Exalidex (TXL)- Dr. R. Foster

Presented at:

HEP DART 2017

Slidesets

Two Doses of HEPLISAV-B™, a Hepatitis B Vaccine with a TLR9 Adjuvant, Compared with Three Doses of Alum-Adjuvanted ENGERIX-B® in Adults Aged 18 -70 Years- Dr. R. Hyer

Presented at:

HEP DART 2017

Slidesets

An Integrated Multidisciplinary Approach for Prediction of Fibrosis Progression and HCC Development in Chronic Hepatitis C Infected Patients Utilizing Genomics, Elastography, Imaging and Circulating Tumor Cells (not yet available)- Dr. E. Thomas

Presented at:

HEP DART 2017

Slidesets

Regulatory landscape for NASH- Veronica Miller

Presented at:

HEP DART 2017

Slidesets

Validation of a novel Transient Elastography for the measurement of liver fibrosis- Dr. J. Dong

Presented at:

HEP DART 2017

Slidesets

Establishment of functional control and normalization of liver function in HBeAg negative chronic HBV infection following combined therapy with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon α-2a.- Dr. A. Vaillant

Presented at:

HEP DART 2017

Slidesets

Strategy for the Elimination of Hepatitis B and C (Academy of Medicine Report)- Andrew Aronsohn, MD

Presented at:

HEP DART 2017

Slidesets

Elimination of HCV: The DC Story- Henry Masur, MD

Presented at:

HEP DART 2017

Slidesets

Eliminating Hepatitis C by 2030 - Enhancing prevention care and treatment among people who inject drugs- Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhD

Presented at:

HEP DART 2017

Slidesets

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition- Anna S. Lok, MD, DSc

Presented at:

HEP DART 2017

Slidesets

Global Strategies to Eliminate Hepatitis B (ICE-HBV)- Peter Revill

Presented at:

HEP DART 2017

Slidesets

Epidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drugs (PWID) in the United States (US): a mathematical model using data from the C-EDGE CO-STAR Study- Dr. M. Robertson

Presented at:

HEP DART 2017

Slidesets

The French and European Approach Towards Hepatitis Elimination- Tarik Asselah, MD, PhD

Presented at:

HEP DART 2017

Slidesets

Novel Nucleosides, CMCP and CFCP, Potently Block the Infectivity and Replication of Wild-type and Drug-resistant HBVs in Culture and in Human-liver-chimeric Mice and Show Potential QW or Q2W (not available)- Dr. H. Mitsuya

Presented at:

HEP DART 2017

Slidesets

Access to HIV, HBV, and HCV Antiviral Agents Globally- John Martin, PhD

Presented at:

HEP DART 2017

Slidesets

DAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination- Jason Grebely

Presented at:

HEP DART 2017

Slidesets

Liver Disease in Chinese-perspective from a Hepatologist- George Lau, MBBS, MRCP, FHKCP, FHKAM, MD, FRCP

Presented at:

HEP DART 2017

Slidesets

A Tale of Two Viruses: HBV and HCV Co-infection (not available)- Jake Liang

Presented at:

HEP DART 2017

Slidesets

The Global Burden of Non-alcoholic Steatohepatitis (not available)- Zobair Younossi

Presented at:

HEP DART 2017

Slidesets

Short Duration DAA HCV Therapy: How Short Can We Go?- Shyam Kottilil, MD, PhD

Presented at:

HEP DART 2017

Slidesets

Elucidating the structural and dynamic mechanism of resistance for clinically relevant variants against HCV NS3/4A protease inhibitors (not available)- Dr. A. Matthew

Presented at:

HEP DART 2017

Slidesets

Real-world utilization and effectiveness of elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada: Z-PROFILE study (not yet available)- Dr. E. Tam

Presented at:

HEP DART 2017

Slidesets

Hepatitis B/C and NASH: Crossroads Between Science and Business (not available)- Geoffrey Meacham

Presented at:

HEP DART 2017